NCT03449381: This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)

NCT03449381
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Brain
Additional Notes: Patient must have tumor with known TP53 wild type status or unknown TP53 status
Exclusions: 
https://ClinicalTrials.gov/show/NCT03449381

Comments are closed.

Up ↑